XML 83 R60.htm IDEA: XBRL DOCUMENT

Supplemental Data (unaudited) (Tables)

12 Months Ended

Dec. 31, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]



For twelve months ended December 31, 2018	DaVita Inc.			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Consolidating Adjustments			Consolidated Total
Dialysis and related lab patient service revenues	$	—		$	7,263,195		$	3,657,456		$	(210,670	)	$	10,709,981
Less: Provision for uncollectible accounts	—			(36,377		)	(13,210		)	—			(49,587		)
Net dialysis and related lab patient service revenues	—			7,226,818			3,644,246			(210,670		)	10,660,394
Other revenues	799,230			714,489			189,927			(959,189		)	744,457
Total net revenues	799,230			7,941,307			3,834,173			(1,169,859		)	11,404,851
Operating expenses and charges	646,640			7,100,415			3,301,831			(1,169,859		)	9,879,027
Operating income	152,590			840,892			532,342			—			1,525,824
Debt expense	(491,749		)	(208,484		)	(36,427		)	249,225			(487,435		)
Other income, net	418,839			10,367			22,195			(441,312		)	10,089
Income tax expense	23,482			187,691			47,227			—			258,400
Equity earnings in subsidiaries	103,196			344,025			—			(447,221		)	—
Net income from continuing operations	159,394			799,109			470,883			(639,308		)	790,078
Net (loss) income from discontinued operations, net of tax	—			(695,913		)	46,788			192,087			(457,038		)
Net income	159,394			103,196			517,671			(447,221		)	333,040
Less: Net income attributable to noncontrolling interests	—			—			—			(173,646		)	(173,646		)
Net income attributable to DaVita Inc.	$	159,394		$	103,196		$	517,671		$	(620,867	)	$	159,394

Consolidating Statements of Income - (continued)



For twelve months ended December 31, 2017	DaVita Inc.			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Consolidating Adjustments			Consolidated Total
Dialysis and related lab patient service revenues	$	—		$	6,884,750		$	3,393,026		$	(184,106	)	$	10,093,670
Less: Provision for uncollectible accounts	—			(340,552		)	(151,982		)	7,170			(485,364		)
Net dialysis and related lab patient service revenues	—			6,544,198			3,241,044			(176,936		)	9,608,306
Other revenues	793,751			1,204,467			68,322			(798,212		)	1,268,328
Total net revenues	793,751			7,748,665			3,309,366			(975,148		)	10,876,634
Operating expenses and charges	527,942			6,475,550			3,035,535			(975,148		)	9,063,879
Operating income	265,809			1,273,115			273,831			—			1,812,755
Debt expense	(426,149		)	(209,612		)	(34,831		)	239,958			(430,634		)
Other income, net	411,731			11,169			18,467			(423,702		)	17,665
Income tax expense	65,965			237,670			20,224			—			323,859
Equity earnings in subsidiaries	478,192			74,375			—			(552,567		)	—
Net income from continuing operations	663,618			911,377			237,243			(736,311		)	1,075,927
Net (loss) income from discontinued operations, net of tax	—			(433,185		)	4,069			183,744			(245,372		)
Net income	663,618			478,192			241,312			(552,567		)	830,555
Less: Net income attributable to noncontrolling interests	—			—			—			(166,937		)	(166,937		)
Net income attributable to DaVita Inc.	$	663,618		$	478,192		$	241,312		$	(719,504	)	$	663,618



For twelve months ended December 31, 2016	DaVita Inc.			Guarantor Subsidiaries			Non- Guarantor Subsidiaries			Consolidating Adjustments			Consolidated Total
Dialysis and related lab patient service revenues	$	—		$	6,665,601		$	3,215,085		$	(153,326	)	$	9,727,360
Less: Provision for uncollectible accounts	—			(272,426		)	(158,878		)	—			(431,304		)
Net dialysis and related lab patient service revenues	—			6,393,175			3,056,207			(153,326		)	9,296,056
Other revenues	767,791			1,378,952			30,184			(765,516		)	1,411,411
Total net revenues	767,791			7,772,127			3,086,391			(918,842		)	10,707,467
Operating expenses and charges	493,175			6,907,469			2,195,955			(918,842		)	8,677,757
Operating income	274,616			864,658			890,436			—			2,029,710
Debt expense	(407,925		)	(191,083		)	(40,434		)	225,326			(414,116		)
Other income, net	396,797			3,726			7,694			(400,706		)	7,511
Income tax expense	77,334			238,446			115,981			—			431,761
Equity earnings in subsidiaries	693,720			667,278			—			(1,360,998		)	—
Net income from continuing operations	879,874			1,106,133			741,715			(1,536,378		)	1,191,344
Net (loss) income from discontinued operations, net of tax	—			(412,413		)	78,771			175,380			(158,262		)
Net income	879,874			693,720			820,486			(1,360,998		)	1,033,082
Less: Net income attributable to noncontrolling interests	—			—			—			(153,208		)	(153,208		)
Net income attributable to DaVita Inc.	$	879,874		$	693,720		$	820,486		$	(1,514,206	)	$	879,874

Condensed Consolidating Statements of Income



For the year ended December 31, 2018	Consolidated Total			Physician Groups			Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Dialysis and related lab patient service revenues	$	10,709,981		$	—		$	—	$	10,709,981
Less: Provision for uncollectible accounts	(49,587		)	—			—		(49,587		)
Net dialysis and related lab patient service revenues	10,660,394			—			—		10,660,394
Other revenues	744,457			—			—		744,457
Total net revenues	11,404,851			—			—		11,404,851
Operating expenses and charges	9,879,027			—			—		9,879,027
Operating income	1,525,824			—			—		1,525,824
Debt expense	(487,435		)	—			—		(487,435		)
Other income, net	10,089			—			—		10,089
Income tax expense	258,400			—			—		258,400
Net income from continuing operations	790,078			—			—		790,078
Net (loss) income from discontinued operations, net of tax	(457,038		)	37,373			92		(494,503		)
Net income	333,040			37,373			92		295,575
Less: Net income attributable to noncontrolling interests	(173,646		)	(7,841		)	—		(165,805		)
Net income attributable to DaVita Inc.	$	159,394		$	29,532		$	92	$	129,770

Consolidating Statements of Comprehensive Income



For the year ended December 31, 2018	DaVita Inc.			Guarantor Subsidiaries		Non- Guarantor Subsidiaries			Consolidating Adjustments			Consolidated Total
Net income	$	159,394		$	103,196	$	517,671		$	(447,221	)	$	333,040
Other comprehensive income (loss)	6,153			—		(45,944		)	—			(39,791		)
Total comprehensive income	165,547			103,196		471,727			(447,221		)	293,249
Less: Comprehensive income attributable to noncontrolling interest	—			—		—			(173,646		)	(173,646		)
Comprehensive income attributable to DaVita Inc.	$	165,547		$	103,196	$	471,727		$	(620,867	)	$	119,603

For the year ended December 31, 2017
Net income	$	663,618		$	478,192	$	241,312		$	(552,567	)	$	830,555
Other comprehensive income	3,106			—		99,770			—			102,876
Total comprehensive income	666,724			478,192		341,082			(552,567		)	933,431
Less: Comprehensive income attributable to noncontrolling interest	—			—		—			(166,935		)	(166,935		)
Comprehensive income attributable to DaVita Inc.	$	666,724		$	478,192	$	341,082		$	(719,502	)	$	766,496

For the year ended December 31, 2016
Net income	$	879,874		$	693,720	$	820,486		$	(1,360,998	)	$	1,033,082
Other comprehensive loss	(290		)	—		(29,337		)	—			(29,627		)
Total comprehensive income	879,584			693,720		791,149			(1,360,998		)	1,003,455
Less: Comprehensive income attributable to noncontrolling interest	—			—		—			(153,398		)	(153,398		)
Comprehensive income attributable to DaVita Inc.	$	879,584		$	693,720	$	791,149		$	(1,514,396	)	$	850,057

Condensed Consolidating Statements of Comprehensive Income



For the year ended December 31, 2018	Consolidated Total			Physician Groups			Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Net income	$	333,040		$	37,373		$	92	$	295,575
Other comprehensive loss	(39,791		)	—			—		(39,791		)
Total comprehensive income	293,249			37,373			92		255,784
Less: Comprehensive income attributable to noncontrolling interest	(173,646		)	(7,841		)	—		(165,805		)
Comprehensive income attributable to DaVita Inc.	$	119,603		$	29,532		$	92	$	89,979

(1)

After the elimination of the unrestricted subsidiaries and the physician groups

Consolidating Balance Sheets



As of December 31, 2018	DaVita Inc.		Guarantor Subsidiaries		Non- Guarantor Subsidiaries		Consolidating Adjustments			Consolidated Total
Cash and cash equivalents	$	60,653	$	—	$	262,385	$	—		$	323,038
Restricted cash and equivalents	1,005		12,048		79,329		—			92,382
Accounts receivable, net	—		1,264,290		594,318		—			1,858,608
Other current assets	37,185		601,318		122,063		—			760,566
Current assets held for sale	—		4,440,953		948,612		—			5,389,565
Total current assets	98,843		6,318,609		2,006,707		—			8,424,159
Property and equipment, net	491,462		1,624,835		1,277,372		—			3,393,669
Intangible assets, net	153		42,933		75,760		—			118,846
Investments in subsidiaries	10,102,750		3,239,862		—		(13,342,612		)	—
Intercompany receivables	3,419,448		—		1,471,203		(4,890,651		)	—
Other long-term assets and investments	53,385		80,537		197,696		—			331,618
Goodwill	—		4,812,365		2,029,595		—			6,841,960
Total assets	$	14,166,041	$	16,119,141	$	7,058,333	$	(18,233,263	)	$	19,110,252
Current liabilities	$	1,945,943	$	1,251,534	$	449,925	$	—		$	3,647,402
Current liabilities held for sale	—		722,766		520,993		—			1,243,759
Total current liabilities	1,945,943		1,974,300		970,918		—			4,891,161
Intercompany payables	—		3,327,026		1,563,625		(4,890,651		)	—
Long-term debt and other long-term liabilities	7,918,581		715,065		552,406		—			9,186,052
Noncontrolling interests subject to put provisions	598,075		—		—		526,566			1,124,641
Total DaVita Inc. shareholders' equity	3,703,442		10,102,750		3,239,862		(13,342,612		)	3,703,442
Noncontrolling interests not subject to put provisions	—		—		731,522		(526,566		)	204,956
Total equity	3,703,442		10,102,750		3,971,384		(13,869,178		)	3,908,398
Total liabilities and equity	$	14,166,041	$	16,119,141	$	7,058,333	$	(18,233,263	)	$	19,110,252

Consolidating Balance Sheets - (continued)



As of December 31, 2017	DaVita Inc.		Guarantor Subsidiaries		Non- Guarantor Subsidiaries		Consolidating Adjustments			Consolidated Total
Cash and cash equivalents	$	149,305	$	—	$	358,929	$	—		$	508,234
Restricted cash and equivalents	1,002		9,384		300		—			10,686
Accounts receivable, net	—		1,208,715		506,035		—			1,714,750
Other current assets	67,025		621,409		86,955		—			775,389
Current assets held for sale	—		4,992,067		769,575		—			5,761,642
Total current assets	217,332		6,831,575		1,721,794		—			8,770,701
Property and equipment, net	408,010		1,560,390		1,180,813		—			3,149,213
Intangible assets, net	250		50,971		62,606		—			113,827
Investments in subsidiaries	10,009,874		3,085,722		—		(13,095,596		)	—
Intercompany receivables	3,677,947		—		1,313,213		(4,991,160		)	—
Other long-term assets and investments	47,297		68,344		214,875		—			330,516
Goodwill	—		4,732,320		1,877,959		—			6,610,279
Total assets	$	14,360,710	$	16,329,322	$	6,371,260	$	(18,086,756	)	$	18,974,536
Current liabilities	$	238,706	$	1,207,482	$	436,262	$	—		$	1,882,450
Current liabilities held for sale	—		739,294		445,776		—			1,185,070
Total current liabilities	238,706		1,946,776		882,038		—			3,067,520
Intercompany payables	—		3,690,042		1,301,118		(4,991,160		)	—
Long-term debt and other long-term liabilities	8,857,373		682,630		469,587		—			10,009,590
Noncontrolling interests subject to put provisions	574,602		—		—		436,758			1,011,360
Total DaVita Inc. shareholders' equity	4,690,029		10,009,874		3,085,722		(13,095,596		)	4,690,029
Noncontrolling interests not subject to put provisions	—		—		632,795		(436,758		)	196,037
Total equity	4,690,029		10,009,874		3,718,517		(13,532,354		)	4,886,066
Total liabilities and equity	$	14,360,710	$	16,329,322	$	6,371,260	$	(18,086,756	)	$	18,974,536

Condensed Consolidating Balance Sheets



As of December 31, 2018	Consolidated Total		Physician Groups		Unrestricted Subsidiaries		Company and Restricted Subsidiaries⁽¹⁾
Cash and cash equivalents	$	323,038	$	—	$	—	$	323,038
Restricted cash and equivalents	92,382		—		—		92,382
Accounts receivable, net	1,858,608		—		—		1,858,608
Other current assets	760,566		—		—		760,566
Other current assets held for sale	5,389,565		532,050		2,825		4,854,690
Total current assets	8,424,159		532,050		2,825		7,889,284
Property and equipment, net	3,393,669		—		—		3,393,669
Amortizable intangibles, net	118,846		—		—		118,846
Other long-term assets	331,618		—		—		331,618
Goodwill	6,841,960		—		—		6,841,960
Total assets	$	19,110,252	$	532,050	$	2,825	$	18,575,377
Current liabilities	$	3,647,402	$	—	$	—	$	3,647,402
Current liabilities held for sale	1,243,759		351,925		—		891,834
Total current liabilities	4,891,161		351,925		—		4,539,236
Payables to parent	—		25,456		2,825		(28,281		)
Long-term debt and other long-term liabilities	9,186,052		—		—		9,186,052
Noncontrolling interests subject to put provisions	1,124,641		—		—		1,124,641
Total DaVita Inc. shareholders' equity	3,703,442		154,669		—		3,548,773
Noncontrolling interests not subject to put provisions	204,956		—		—		204,956
Shareholders' equity	3,908,398		154,669		—		3,753,729
Total liabilities and shareholders' equity	$	19,110,252	$	532,050	$	2,825	$	18,575,377

Consolidating Statements of Cash Flows

Consolidating Statements of Cash Flow



For the year ended December 31, 2018	DaVita Inc.			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Consolidated Total
Cash flows from operating activities:
Net income	$	159,394		$	103,196		$	517,671		$	(447,221	)	$	333,040
Changes in operating assets and liabilities and non-cash items included in net income	(86,070		)	818,027			259,422			447,221			1,438,600
Net cash provided by operating activities	73,324			921,223			777,093			—			1,771,640
Cash flows from investing activities:
Additions of property and equipment, net	(175,787		)	(534,278		)	(277,073		)	—			(987,138		)
Acquisitions	—			(73,046		)	(110,110		)	—			(183,156		)
Proceeds from asset sales, net of cash divested	—			61,962			88,243			—			150,205
Investments and other items	30,962			(16,362		)	(154		)	—			14,446
Net cash used in investing activities	(144,825		)	(561,724		)	(299,094		)	—			(1,005,643		)
Cash flows from financing activities:
Long-term debt and related financing costs, net	725,889			(11,437		)	(19,675		)	—			694,777
Intercompany borrowing	404,897			(311,778		)	(93,119		)	—			—
Other items	(1,147,934		)	(28,067		)	(144,130		)	—			(1,320,131		)
Net cash used in financing activities	(17,148		)	(351,282		)	(256,924		)	—			(625,354		)
Effect of exchange rate changes on cash	—			—			(3,350		)	—			(3,350		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(88,649		)	8,217			217,725			—			137,293
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations	—			5,553			235,240			—			240,793
Net (decrease) increase in cash, cash equivalents and restricted cash from continuing operations	(88,649		)	2,664			(17,515		)	—			(103,500		)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year	150,307			9,384			359,229			—			518,920
Cash, cash equivalents and restricted cash of continuing operations at end of the year	$	61,658		$	12,048		$	341,714		$	—		$	415,420

Consolidating Statements of Cash Flow - (continued)



For the year ended December 31, 2017	DaVita Inc.			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Consolidated Total
Cash flows from operating activities:
Net income	$	663,618		$	478,192		$	241,312		$	(552,567	)	$	830,555
Changes in operating assets and liabilities and non-cash items included in net income	(533,300		)	368,135			695,209			552,567			1,082,611
Net cash provided by operating activities	130,318			846,327			936,521			—			1,913,166
Cash flows from investing activities:
Additions of property and equipment, net	(155,972		)	(490,800		)	(258,478		)	—			(905,250		)
Acquisitions	—			(693,522		)	(110,357		)	—			(803,879		)
Proceeds from asset and business sales, net of cash divested	—			90,340			1,996			—			92,336
Investments and other items	211,619			(7,004		)	47,446			—			252,061
Net cash provided by (used in) investing activities	55,647			(1,100,986		)	(319,393		)	—			(1,364,732		)
Cash flows from financing activities:
Long-term debt and related financing costs, net	173,529			(12,662		)	(6,019		)	—			154,848
Intercompany borrowing	22,589			218,980			(241,569		)	—			—
Other items	(781,697		)	(2,493		)	(136,915		)	—			(921,105		)
Net cash (used in) provided by financing activities	(585,579		)	203,825			(384,503		)	—			(766,257		)
Effect of exchange rate changes on cash	—			—			254			—			254
Net (decrease) increase in cash, cash equivalents and restricted cash	(399,614		)	(50,834		)	232,879			—			(217,569		)
Less: Net decrease in cash, cash equivalents and restricted cash from discontinued operations	—			(51,531		)	(1,495		)	—			(53,026		)
Net (decrease) increase in cash, cash equivalents and restricted cash from continuing operations	(399,614		)	697			234,374			—			(164,543		)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year	549,921			8,687			124,855			—			683,463
Cash, cash equivalents and restricted cash of continuing operations at end of the year	$	150,307		$	9,384		$	359,229		$	—		$	518,920

Consolidating Statements of Cash Flow - (continued)



For the year ended December 31, 2016	DaVita Inc.			Guarantor Subsidiaries			Non-Guarantor Subsidiaries			Consolidating Adjustments			Consolidated Total
Cash flows from operating activities:
Net income	$	879,874		$	693,720		$	820,486		$	(1,360,998	)	$	1,033,082
Changes in operating assets and liabilities and non-cash items included in net income	(612,706		)	359,366			(168,614		)	1,360,998			939,044
Net cash provided by operating activities	267,168			1,053,086			651,872			—			1,972,126
Cash flows from investing activities:
Additions of property and equipment, net	(139,303		)	(382,305		)	(307,487		)	—			(829,095		)
Acquisitions	—			(472,413		)	(91,443		)	—			(563,856		)
Proceeds from asset sales	—			70,342			(5,617		)	—			64,725
Investments and other items	153,031			(29,038		)	2,565			—			126,558
Net cash provided by (used in) investing activities	13,728			(813,414		)	(401,982		)	—			(1,201,668		)
Cash flows from financing activities:
Long-term debt and related financing costs, net	(92,460		)	(27,830		)	(4,152		)	—			(124,442		)
Intercompany borrowing	236,052			(231,800		)	(4,252		)	—			—
Other items	(1,061,203		)	(21,525		)	(144,811		)	—			(1,227,539		)
Net cash used in financing activities	(917,611		)	(281,155		)	(153,215		)	—			(1,351,981		)
Effect of exchange rate changes on cash	—			—			4,276			—			4,276
Net (decrease) increase in cash, cash equivalents and restricted cash	(636,715		)	(41,483		)	100,951			—			(577,247		)
Less: Net (decrease) increase in cash, cash equivalents and restricted cash from discontinued operations	—			(50,170		)	34,377			—			(15,793		)
Net (decrease) increase in cash, cash equivalents and restricted cash from continuing operations	(636,715		)	8,687			66,574			—			(561,454		)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year	1,186,636			—			58,281			—			1,244,917
Cash, cash equivalents and restricted cash of continuing operations at end of the year	$	549,921		$	8,687		$	124,855		$	—		$	683,463

Condensed Consolidating Statements of Cash Flow



For the year ended December 31, 2018	Consolidated Total			Physician Groups			Unrestricted Subsidiaries			Company and Restricted Subsidiaries⁽¹⁾
Cash flows from operating activities:
Net income	$	333,040		$	37,373		$	92		$	295,575
Changes in operating and intercompany assets and liabilities and non-cash items included in net income	1,438,600			81,722			(92		)	1,356,970
Net cash provided by operating activities	1,771,640			119,095			—			1,652,545
Cash flows from investing activities:
Additions of property and equipment	(987,138		)	(2,746		)	—			(984,392		)
Acquisitions and divestitures, net	(183,156		)	—			—			(183,156		)
Proceeds from asset sales	150,205			—			—			150,205
Investments and other items, net	14,446			(154		)	—			14,600
Net cash used in investing activities	(1,005,643		)	(2,900		)	—			(1,002,743		)
Cash flows from financing activities:
Long-term debt and related financing costs, net	694,777			—			—			694,777
Intercompany	—			25,296			—			(25,296		)
Other items	(1,320,131		)	—			—			(1,320,131		)
Net cash (used in) provided by financing activities	(625,354		)	25,296			—			(650,650		)
Effect of exchange rate changes on cash	(3,350		)	—			—			(3,350		)
Net increase (decrease) in cash, cash equivalents and restricted cash	137,293			141,491			—			(4,198		)
Less: Net increase in cash, cash equivalents and restricted cash from discontinued operations	240,793			141,491			—			99,302
Net decrease in cash, cash equivalents and restricted cash from continuing operations	(103,500		)	—			—			(103,500		)
Cash, cash equivalents and restricted cash of continuing operations at beginning of the year	518,920			—			—			518,920
Cash, cash equivalents and restricted cash of continuing operations at end of the year	$	415,420		$	—		$	—		$	415,420

(1)

After the elimination of the unrestricted subsidiaries and the physician groups